(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Augment the Advantages of a Web-based Degree - 2Reactions as Artemis II astronauts lift off on historic lunar mission
- 3Pick Your Number one breakfast food
- 4Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- 5Vote in favor of the subject that you see as generally captivating and intelligent!
- Surveys of Thrillers That Re-imagined the Class
- Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- Europe: 4 Urban communities for a Paramount Social Experience
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- 6 Top Computer game Control center
- Antivirus Programming for Exhaustive Security
- Climbing Mount Everest: An Individual Victory
- Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side
